An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine
- PMID: 8892925
- PMCID: PMC190874
- DOI: 10.1128/JVI.70.11.8010-8018.1996
An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine
Abstract
Sequencing of the reverse transcriptase (RT) region of 26 human immunodeficiency virus type 1 (HIV-1) isolates from eight patients treated with 3'-azido-3'-deoxythymidine (AZT) revealed a mutation at codon 210 from TTG (leucine) to TGG (tryptophan) exclusively in association with resistance to AZT. The mutation Trp-210 was observed in 15 of the 20 isolates phenotypically resistant to AZT, being more commonly observed than resistance-associated mutations at codons 67, 70, and 219. Trp-210 was never observed before the emergence of resistance-associated mutations Leu-41 and Tyr-215, and in a sequential series of five isolates from one patient the order of emergence of mutations was found to be Tyr-215, Leu-41, and then Trp-210. Trp-210 was also found in association with the Leu-41, Asn-67, Arg-70, and Tyr-215 resistance genotype. To define the role of Trp-210 in AZT resistance, molecular HIV-1 clones were constructed with various combinations of RT mutations at codons 41, 67, 70, 210, and 215 and tested for susceptibility to AZT. In clones with polymerase genes derived either from HXB2-D or clinical isolates, Trp-210 alone did not increase AZT resistance, whereas in conjunction with Leu-41 and Tyr-215, Trp-210 contributed to high-level resistance (50% inhibitory concentration of >1 microM). In HXB2-D, Trp-210 with Tyr-215 generated a virus with resistance comparable to one with Leu-41, Tyr-215, and Trp-210. Inserting Trp-210 into the genetic context of mutations at codons 41, 67, 70, and 215 further enhanced resistance from a 50% inhibitory concentration of 1.44 microM to 8.41 microM. Molecular modeling of the tertiary structure of HIV-1 RT revealed that the distance between the side chains of Trp-210 (in helix alphaF) and Tyr-215 (in strand beta11a) approximated 4 A (1 A = 0.1 nm), sufficiently close to result in significant energetic interaction between these two aromatic side chains. In conclusion, Trp-210 contributes significantly to phenotypic AZT resistance of HIV-1 by augmenting resistance at least three- to sixfold in the context of two resistant genotypes, and its effect may require an interaction with an aromatic amino acid at position 215.
Similar articles
-
Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.J Virol. 2004 Jul;78(14):7545-52. doi: 10.1128/JVI.78.14.7545-7552.2004. J Virol. 2004. PMID: 15220429 Free PMC article.
-
Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance.EMBO J. 2000 Nov 1;19(21):5752-61. doi: 10.1093/emboj/19.21.5752. EMBO J. 2000. PMID: 11060026 Free PMC article.
-
Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.J Virol. 2004 Sep;78(18):9987-97. doi: 10.1128/JVI.78.18.9987-9997.2004. J Virol. 2004. PMID: 15331732 Free PMC article.
-
Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1.Clin Invest Med. 1994 Jun;17(3):226-43. Clin Invest Med. 1994. PMID: 7523016 Review.
-
Failure of antiretroviral therapy: role of viral and cellular factors.Intervirology. 1994;37(6):307-14. doi: 10.1159/000150394. Intervirology. 1994. PMID: 8586528 Review.
Cited by
-
Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.Retrovirology. 2008 Feb 13;5:20. doi: 10.1186/1742-4690-5-20. Retrovirology. 2008. PMID: 18271957 Free PMC article.
-
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.Antimicrob Agents Chemother. 1998 Jul;42(7):1620-8. doi: 10.1128/AAC.42.7.1620. Antimicrob Agents Chemother. 1998. PMID: 9660994 Free PMC article. Clinical Trial.
-
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.J Virol. 1998 May;72(5):3773-8. doi: 10.1128/JVI.72.5.3773-3778.1998. J Virol. 1998. PMID: 9557659 Free PMC article.
-
Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase.PLoS One. 2012;7(2):e31558. doi: 10.1371/journal.pone.0031558. Epub 2012 Feb 21. PLoS One. 2012. PMID: 22363673 Free PMC article. Clinical Trial.
-
Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1.Antimicrob Agents Chemother. 2002 Dec;46(12):3861-8. doi: 10.1128/AAC.46.12.3861-3868.2002. Antimicrob Agents Chemother. 2002. PMID: 12435689 Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases